Relationship between coagulation parameters and tumor markers and venous thromboembolism in different stages of malignant tumors
HE Lili CAO Guolei LUO Qin▲
Department of Integrated Internal Medicine, the Third Clinical Medical College, Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi 830011, China
Abstract：Objective To explore the relationship between coagulation parameters and tumor markers and venous thromboembolism (VTE) in different stages of malignant tumors. Methods A total of 233 patients with malignant tumors complicated with VTE who admitted to the Third Clinical Medical College of Xinjiang Medical University from May 2013 to January 2017 were selected as research objects. According to the malignant tumor TNM staging criteria, they were divided into group Ⅰ (17 cases), group Ⅱ (17 cases), group Ⅲ (54 cases), group Ⅳ (145 cases). D-dimer (D-D), prothrombin time (PT), activated partial prothrombin time (APTT), fibrinogen (Fbg), international normalized ration (INR) and Glycan 19-9 (CA19-9), CA125, Carcinoembryonic Antigen (CEA) were compared between four groups. Results D-D value in group Ⅲ was higher than that in groupⅠ-Ⅱ (P < 0.05); D-D value in group Ⅳ was higher than that in group Ⅰ-Ⅲ (P < 0.05); and there were no significant differences in PT, APTT, Fbg, INR levels between four groups (P > 0.05). CA19-9 levels in group Ⅲ were higher than those in group Ⅱ (P < 0.05); CA19-9, CA125 levels in group Ⅳ were higher than those in group Ⅰ-Ⅲ (P < 0.05); CEA levels in group Ⅲ-Ⅳ were higher than those in group Ⅰ-Ⅱ (P < 0.05). Conclusion Patients with late stage should pay more attention to D-D and CA19-9, CA125 and CEA levels, and the detection frequency can be appropriately increased to monitor their thrombus status.
何丽丽 曹国磊 罗琴▲. 凝血指标及肿瘤标志物与不同分期恶性肿瘤合并静脉血栓栓塞症的关系[J]. 中国医药导报, 2020, 17(17): 117-120.
HE Lili CAO Guolei LUO Qin▲. Relationship between coagulation parameters and tumor markers and venous thromboembolism in different stages of malignant tumors. 中国医药导报, 2020, 17(17): 117-120.
[1] Khorana AA. The NCCN clinical practice guidelines on venous thromboembolic disease：strategies for improving VTE prophylaxis in hospitalized cancer patients [J]. Oncologist，2007，12（11）：1361-1370.
[2] Pabinger I，Thaler J，Ay C. Biomarkers for prediction of venous thromboembolism in cancer [J]. Blood，2013，122（12）：2011-2018.
[3] 门剑龙，钟殿胜，任静.血栓标志物评估恶性肿瘤患者静脉血栓风险[J].中华肿瘤杂志，2015，37（4）：283-289.
[4] Zhang Y，Yang Y，Chen W，et al. Prevalence and associations of VTE in patients with newly diagnosed lung cancer [J]. Chest，2014，146（3）：650-658
[5] Saadeh FA，Norris L，O′Toole S，et al. Venous thromboembolism in ovarian cancer：incidence，risk factors and impact on survival [J]. Eur J Obstet Gynecol Reprod Biol，2013，170（1）：214-218.
[6] Awkar N，Amireh S，Rai S，et al. Association between level of tumor markers and development of VTE in patients with pancreatic，colorectal and ovarian ca：retrospective case-control study in two community hospitals [J]. Pathol Oncol Res，2018，24（2）：283-287.
[7] 方芳，林云才.老年肺癌合并静脉血栓栓塞症的因素及生存情况[J].中国老年学杂志，2016，36（17）：4253-4254.
[8] Edge SB，Compton CC. The American joint committee on cancer：the 7th edition of the AJCC cancer staging manual and the future of TNM [J]. Ann Surg Oncol，2010，17（6）：1471-1474.
[9] Li Q，Xue Y，Peng Y，et al. Analysis of risk factors for deep venous thrombosis in patients with gynecological malignant tumor：A clinical study [J]. Pak J Med Sci，2019，35（1）：195-199.
[10] 秦霞，田利，李惠玲，等.内科住院病人发生静脉血栓栓塞症危险因素的Meta分析[J].现代预防医学，2018，45（4）：753-756.
[11] Ahlbrecht J，Dickmann B，Ay C，et al. Tumor grade is associated with venous thromboembolism in patients with cancer：results from the Vienna Cancer and Thrombosis Study [J]. J Clin Oncol，2012，30（31）：3870-3875.
[12] 王丽丽，刘峰，张燕捷，等.血浆D-二聚体水平与恶性肿瘤患者发生静脉血栓的相关性[J].现代肿瘤医学，2018，26（9）：1427-1431.
[13] Iorio A，Kearon C，Filippucci E，et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor：a systematic review[J]. Arch Int Med，2010，170（19）：1710-1716.
[14] Johnsen HS，Hindberg K，Bj?覬ri E，et al. D-Dimer Measured at Diagnosis of Venous Thromboembolism is Associated with Risk of Major Bleeding [J]. TH Open，2019，3（1）：e77-e84.
[15] 叶炜，陈跃鑫，李鸣，等.不明原因静脉血栓栓塞症患者进行血清肿瘤标志物筛查的临床意义[J].中华医学杂志，2014，94（15）：1143-1146.
[16] Li F，Li S，Wei L，et al. The correlation between pre-operative serum tumor markers and lymph node metastasis in gastric cancer patients undergoing curative treatment [J]. Biomarkers，2013，18（7）：632-637.
[17] Khorana AA，Kuderer NM，Culakova E，et al. Development and validation of a predictive model for chemotherapy-associated thrombosis [J]. Blood，2008，111（10）：4902-4907.
[18] Ay C，Dunkler D，Marosi C，et al. Prediction of venous thromboembolism in cancer patients [J]. Blood，2010，116（24）：5377-5382.
[19] 李金玲，代俊利，姜峰，等.肺癌合并静脉血栓栓塞症37例临床调查分析[J].重庆医学，2015，44（34）：4790-4792，4795.
[20] 闵翼，许雄伟.妇科肿瘤患者抗凝药物预防静脉血栓栓塞的现况特点及合理性分析[J].中国医药科学，2019，9（7）：57-60.
2020, Vol. 17 
京公网安备 11010502046598号